Featured Publications
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis
Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, Sos P, Wang G, Zarate CA, Sanacora G. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. American Journal Of Psychiatry 2017, 175: 150-158. PMID: 28969441, PMCID: PMC5794524, DOI: 10.1176/appi.ajp.2017.17040472.Peer-Reviewed Original ResearchConceptsIndividual participant dataLong-term safetySuicidal ideationKetamine effectsSingle doseParticipant dataSuicide itemOutcome measuresSystematic reviewIndividual Participant Data Meta-AnalysisLimited treatment optionsPrimary outcome measureSelf-reported outcome measuresData Meta-AnalysisIntravenous ketaminePublic health crisisKetamine administrationTreatment optionsQIDS-SRDepressed patientsDepressive symptomsIntervention studiesKetamineMeta-AnalysisSuicidal thoughts
2023
The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression
Lineham A, Avila-Quintero V, Bloch M, Dwyer J. The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression. Journal Of Child And Adolescent Psychopharmacology 2023, 33: 20-26. PMID: 36799961, DOI: 10.1089/cap.2022.0086.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionDepression symptom improvementAcute dissociative symptomsAntidepressant responseSymptom improvementRapid-acting antidepressant agentsSignificant associationDissociative symptomsLikelihood of responseDissociation symptomsMagnitude of associationDissociative effectsKetamine groupPediatric patientsCrossover trialPediatric populationAntidepressant agentsKetamine responseAdolescent patientsAdult studiesDepression responseSecondary data analysisTreatment responseDepressive symptomsTrial design
2021
Meta-Analysis: Pediatric Placebo Response in Depression Trials Does Not Replicate in Anxiety and Obsessive-Compulsive Disorder Trials
Nasir M, Li F, Courley S, Olten B, Bloch MH. Meta-Analysis: Pediatric Placebo Response in Depression Trials Does Not Replicate in Anxiety and Obsessive-Compulsive Disorder Trials. Journal Of Child And Adolescent Psychopharmacology 2021, 31: 670-684. PMID: 34558984, DOI: 10.1089/cap.2021.0030.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnxietyAnxiety DisordersChildDepressionHumansObsessive-Compulsive DisorderPlacebo EffectConceptsPlacebo response ratesObsessive-compulsive disorderPlacebo responseDepression trialsResponse ratePlacebo improvementSymptom improvementAntidepressant trialsStratified subgroup analysisRandom-effects modelPediatric populationSubgroup analysisStudy visitNumber of subjectsPsychopharmacological trialsPubMed searchDifferent indicationsDiagnostic indicationsMean differenceAnxiety disordersTrialsDisordersPediatric anxietyPredictorsPossible correlatesEditorial: Money cannot buy happiness – but can it prevent depression? A commentary on Su et al.
Nasir M, Bloch MH. Editorial: Money cannot buy happiness – but can it prevent depression? A commentary on Su et al. Journal Of Child Psychology And Psychiatry 2021, 62: 1047-1049. PMID: 34448198, DOI: 10.1111/jcpp.13507.Peer-Reviewed Original ResearchConceptsRisk factorsSystematic reviewLow birth weightSmall gestational ageRisk of depressionDevelopmental risk factorsGestational agePostnatal exposurePremature birthParental smokingBirth weightPrenatal depressionMaternal anxietyMaternal stressMaternal educationSocioeconomic statusDepressionParental ageDevelopmental originsPotential exposureAgeReviewExposureOffspringSmokingDon’t Forget, Untreated Maternal Depression Poses Health Risks to the Child, Too
Behling E, Bloch MH. Don’t Forget, Untreated Maternal Depression Poses Health Risks to the Child, Too. Biological Psychiatry 2021, 90: 212-213. PMID: 34325804, DOI: 10.1016/j.biopsych.2021.06.010.Peer-Reviewed Original Research
2019
Meta-analysis of placebo group dropout in adult antidepressant trials
Li F, Nasir M, Olten B, Bloch MH. Meta-analysis of placebo group dropout in adult antidepressant trials. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2019, 98: 109777. PMID: 31697973, DOI: 10.1016/j.pnpbp.2019.109777.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderPlacebo leadAntidepressant trialsDiagnostic indicationsPlacebo-controlled trialStratified subgroup analysisBaseline illness severityMore study visitsDropout rateOverall dropout rateFreeman-Tukey transformationLonger trial durationEarlier publication yearPlacebo groupIllness severitySubgroup analysisDepressive disorderStudy visitMeta-AnalysisTrial durationAnxiety disordersTrialsEfficiency of trialsSubject burdenDisordersMeta-Analysis of Placebo Response in Adult Antidepressant Trials
Li F, Nasir M, Olten B, Bloch MH. Meta-Analysis of Placebo Response in Adult Antidepressant Trials. CNS Drugs 2019, 33: 971-980. PMID: 31573058, DOI: 10.1007/s40263-019-00662-y.Peer-Reviewed Original ResearchConceptsPlacebo response ratesPlacebo improvementSymptom improvementObsessive-compulsive disorderResponse rateDiagnostic indicationsAntidepressant trialsRandomized placebo-controlled trialPlacebo-controlled trialStratified subgroup analysisSecond-generation antidepressantsPlacebo comparison groupFuture antidepressantsSubgroup analysisClinical trialsPlacebo responseTrial characteristicsGreater magnitudeDepression trialsMeta-AnalysisUS sitesTrial durationAntidepressantsLanguage limitsMean difference
2018
Editorial: Can omega‐3 fatty acids improve executive functioning? Will this reduce ADHD and depression?
Artukoglu BB, Bloch MH. Editorial: Can omega‐3 fatty acids improve executive functioning? Will this reduce ADHD and depression? Journal Of Child Psychology And Psychiatry 2018, 59: 615-617. PMID: 29808491, DOI: 10.1111/jcpp.12932.Peer-Reviewed Original ResearchA Systematic Review of Pharmacologic Treatments for School Refusal Behavior
Tobon A, Reed MO, Taylor JH, Bloch MH. A Systematic Review of Pharmacologic Treatments for School Refusal Behavior. Journal Of Child And Adolescent Psychopharmacology 2018, 28: 368-378. PMID: 29741917, PMCID: PMC6909768, DOI: 10.1089/cap.2017.0160.Peer-Reviewed Original ResearchConceptsSchool refusalSystematic reviewPharmacologic treatmentFuture pharmacologic studiesSpecific psychosocial treatmentsLong-term outcomesNew pharmacologic agentsImportant pediatric problemSchool refusal behaviorComprehensive literature searchSignificant methodological limitationsImportant functional outcomesSecondary outcomesFunctional outcomeNewer antidepressantsPharmacologic trialsPharmacological treatmentPharmacologic agentsPharmacological interventionsPsychological interventionsPharmacologic studiesPsychosocial treatmentsMost trialsPediatric problemAnxiety symptomsMeta-analysis: Second generation antidepressants and headache
Telang S, Walton C, Olten B, Bloch MH. Meta-analysis: Second generation antidepressants and headache. Journal Of Affective Disorders 2018, 236: 60-68. PMID: 29715610, DOI: 10.1016/j.jad.2018.04.047.Peer-Reviewed Original ResearchConceptsRisk of headacheSecond-generation antidepressantsAntidepressant medicationGeneration antidepressantsSide effectsTreatment-emergent side effectsPlacebo-controlled trialPooled risk ratioFixed-dose trialStratified subgroup analysisTreatment of adultsDosage of medicationReceptor affinity profileSignificant differencesMeta-analysis resultsOnly antidepressantsMedication classesMedication dosingMedication typeObsessive-compulsive disorderSubgroup analysisRisk ratioRelative riskHeadacheMedications
2016
Addressing Difficulties in the Study of Dose-Response Relationships of SSRIs in Depression: Response to Hieronymus and Eriksson
Jakubovski E, Bloch MH. Addressing Difficulties in the Study of Dose-Response Relationships of SSRIs in Depression: Response to Hieronymus and Eriksson. American Journal Of Psychiatry 2016, 173: 836-838. PMID: 27477138, DOI: 10.1176/appi.ajp.2016.16030304r.Peer-Reviewed Original ResearchN-Acetylcysteine in the Treatment of Pediatric Tourette Syndrome: Randomized, Double-Blind, Placebo-Controlled Add-On Trial
Bloch MH, Panza KE, Yaffa A, Alvarenga PG, Jakubovski E, Mulqueen JM, Landeros-Weisenberger A, Leckman JF. N-Acetylcysteine in the Treatment of Pediatric Tourette Syndrome: Randomized, Double-Blind, Placebo-Controlled Add-On Trial. Journal Of Child And Adolescent Psychopharmacology 2016, 26: 327-334. PMID: 27027204, PMCID: PMC6445198, DOI: 10.1089/cap.2015.0109.Peer-Reviewed Original ResearchConceptsBenefit of NACEfficacy of NACYale Global Tic Severity ScaleAttention-deficit/hyperactivity disorderObsessive-compulsive disorderTourette syndromeN-acetylcysteineObsessive-compulsive spectrum disordersSide effectsRecent placebo-controlled trialPediatric Tourette syndromePlacebo-controlled trialCurrent pharmacological treatmentsTreatment of ticsTotal tic scoreSeverity of ticsSubstantial side effectsTic Severity ScaleYears of ageMinimal side effectsPediatric TSPrimary outcomeSecondary outcomesGlutamatergic systemPharmacological treatment
2015
LONG‐TERM OUTCOME IN PEDIATRIC TRICHOTILLOMANIA
Schumer MC, Panza KE, Mulqueen JM, Jakubovski E, Bloch MH. LONG‐TERM OUTCOME IN PEDIATRIC TRICHOTILLOMANIA. Depression And Anxiety 2015, 32: 737-743. PMID: 26139231, PMCID: PMC4591183, DOI: 10.1002/da.22390.Peer-Reviewed Original ResearchConceptsPoor long-term prognosisLong-term prognosisLong-term outcomesN-acetylcysteineDepressive symptomsPediatric trichotillomaniaTrichotillomania symptomsOlder ageAdequate symptom reliefPlacebo-controlled trialAnxiety symptomsPredictors of outcomePrevious cross-sectional studiesRisk of depressionCross-sectional studyPrimary outcomeSymptom reliefAcute phaseClinical assessmentTreatment utilizationBaseline evaluationSecondary measuresBaseline assessmentSymptomsBehavioral treatment
2012
Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder
Bloch MH, Wasylink S, Landeros-Weisenberger A, Panza KE, Billingslea E, Leckman JF, Krystal JH, Bhagwagar Z, Sanacora G, Pittenger C. Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder. Biological Psychiatry 2012, 72: 964-970. PMID: 22784486, PMCID: PMC3667652, DOI: 10.1016/j.biopsych.2012.05.028.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderKetamine infusionDepression symptomsLow-dose ketamine infusionTreatment-refractory obsessive-compulsive disorderOCD symptomsPathogenesis of OCDIncomplete symptom reliefTreatment-Refractory ObsessiveOpen-label trialRapid antidepressant effectsAspartate glutamate receptorsEffects of ketaminePotent noncompetitive antagonistGlutamate abnormalitiesAntidepressant effectsAntidepressant responseSymptom reliefKetamine effectsComorbid depressionAcute effectsGlutamate receptorsDepressive symptomsNoncompetitive antagonistInfusion